Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)
Phase 3
Terminated
- Conditions
- Contraception
- Interventions
- Drug: LNG-EE 150 μg/30 μg COCDrug: ENG-E2 125 μg/300 μg vaginal ring
- First Posted Date
- 2015-11-26
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 2016
- Registration Number
- NCT02616146
- Locations
- 🇦🇹
MSD Osterreich GmbH, Vienna, Austria
🇩🇰Merck Sharp & Dohme, Glostrup, Denmark
🇫🇮MSD Finland Oy, Espoo, Finland
A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Behavioral: Diet control/Daily Exercise
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 309
- Registration Number
- NCT02550288
Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring in Women at Risk for Pregnancy (MK-8342B-061)
Phase 3
Terminated
- Conditions
- Contraception
- Interventions
- Drug: ENG-E2 125 μg/300 μg vaginal ring
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1941
- Registration Number
- NCT02524288
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)
Phase 3
Completed
- Conditions
- Heterozygous Familial HypercholesterolemiaHypercholesterolemia
- Interventions
- Drug: EZ 10 mg/Atorva 10 mg FDCDrug: EZ 10 mg/Atorva 20 mg FDC
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 135
- Registration Number
- NCT02460159
Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Seasonal Allergic Rhinitis (MK-4117-204)
Phase 3
Completed
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-12-19
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 449
- Registration Number
- NCT02320396
Performance and Safety of Vaginal Ring Applicator in Healthy Females (MK-8342A-063)
Phase 3
Completed
- Conditions
- Contraception: Optional Applicator for Insertion of Vaginal Ring
- Interventions
- Drug: Placebo vaginal ringDevice: Single-use, non-sterile applicator
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 164
- Registration Number
- NCT02275546
A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis
Phase 1
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: E6005 0.2%Drug: PlaceboDrug: E6005 0.05%
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 62
- Registration Number
- NCT02094235
The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168)
Phase 1
Completed
- Conditions
- Osteoarthritis Pain
- Interventions
- Drug: PlaceboDrug: Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 70
- Registration Number
- NCT01980940
A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)
Phase 3
Completed
- Conditions
- Perennial Allergic Rhinitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-08-07
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 608
- Registration Number
- NCT01918033
Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 94
- Registration Number
- NCT01916980